Cargando…
CodeBreak 200: Sotorasib Has Not Broken the KRAS(G12C) Enigma Code
Thirteen percent of non-small cell lung cancer (NSCLC) patients are estimated to have the KRAS G12C mutation. Sotorasib is a novel KRAS G12C inhibitor that has shown promising results in preclinical and clinical studies, granting its conditional approval by the FDA in May 2021. The phase I clinical...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123019/ https://www.ncbi.nlm.nih.gov/pubmed/37101895 http://dx.doi.org/10.2147/LCTT.S403461 |